Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

被引：3
|
作者：
Piratvisuth, T.
Lau, G. K. K.
Marcellin, P.
Chow, W. C.
Cooksley, G.
Fried, M. W.
Paik, S. W.
Liaw, Y. F.
Popescu, M.
Button, P.
机构：
[1] Prince Songkla Univ, Dept Internal Med, Songklanagarind Hosp, Hat Yai, Thailand
[2] Univ Hong Kong, Queen Marys Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Hop Beaujon, Serv Hepatol, Clichy, France
[4] Singapore Gen Hosp, Dept Gastroenterol, Singapore 0316, Singapore
[5] Royal Brisbane Hosp, Dept Clin Res, Brisbane, Qld 4029, Australia
[6] Univ N Carolina, Univ N Carolina Liver Program, Chapel Hill, NC USA
[7] Samsung Med Ctr, Dept Gastroenterol, Seoul, South Korea
[8] Chang Gung Mem Hosp, Linkou, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2006年 / 44卷
关键词：
D O I：
10.1016/S0168-8278(06)80050-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
49
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [31] HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
    Peng, Cheng-Yuan
    Hsieh, Tsung-Cheng
    Hsieh, Tsai-Yuan
    Tseng, Kuo-Chih
    Lin, Chih-Lin
    Su, Tung-Hung
    Tseng, Tai-Chung
    Lin, Hans Hsienhong
    Wang, Chia-Chi
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (04) : 308 - 313
  • [32] Association between Genotype and the HBsAg Levels at HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir or Peginterferon Alfa-2a
    Peng, Cheng-Yuan
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Lin, Chia-Hsin
    Chuang, Po-Heng
    Chen, Sheng-Hung
    HEPATOLOGY, 2014, 60 : 1121A - 1121A
  • [33] STRONGER HBV DNA SUPPRESSION IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B ACHIEVING HBEAG CLEARANCE DURING PEGINTERFERON ALFA-2B THERAPY COMPARED WITH PLACEBO
    Hansen, Bettina E.
    Rijckborst, Vincent
    ter Borg, Martijn J.
    Janssen, Harry L.
    HEPATOLOGY, 2010, 52 (04) : 563A - 563A
  • [34] ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a (40KD) (PEGASYS®) are not necessary for a significant response to therapy.
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2003, 38 (04) : 724A - 724A
  • [35] HBV-DNA and infected hepatocytes dynamics in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combination therapy using a new bio-mathematical model
    Colombatto, P
    Bizzarri, R
    Civitano, L
    Oliveri, F
    Bonino, F
    Germanidis, G
    Farci, P
    Kitis, G
    Hadziannis, S
    Choudhury, S
    Gieschke, R
    Zahm, F
    Brunetto, M
    HEPATOLOGY, 2004, 40 (04) : 666A - 667A
  • [36] TELBIVUDINE SUPPRESSED HBV DNA AND HBEAG SIMULTANEOUSLY IN HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS, A TWO-CENTER CLINICAL STUDY
    Dou, Xiaoguang
    Ding, Yang
    Wang, Shulan
    Sheng, Qiuju
    Wang, Jingyang
    Shi, Lilan
    HEPATOLOGY, 2009, 50 (04) : 543A - 543A
  • [37] HIGH LEVELS OF HBSAG AND HBV DNA DURING TREATMENT PREDICT FAILURE FOR HBEAG SEROCONVERSION IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 541A - 541A
  • [38] A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin
    Colombatto, P
    Bizzarri, R
    Civitano, L
    Oliveri, F
    Bonino, F
    Germanidis, G
    Farci, P
    Kitis, G
    Hadziyannis, S
    Choudhury, S
    Gieschke, R
    Zahm, F
    Brunetto, M
    JOURNAL OF HEPATOLOGY, 2004, 40 : 125 - 125
  • [39] Suppression of HBV DNA in patients with HBeAg-negative CHB treated with peginterferon alfa-2A (40KD) ± lamivudine:: 2-year follow-up results
    Marcellin, Patrick
    Bonino, Ferruccio
    Lau, George K.
    Farci, Patrizia
    Yurdaydin, Cihan
    Piratvisuth, Teerha
    Luo, Kangxian
    Gurel, Selim
    Hadziyannis, Stephanos
    Wang, Yuming
    Popescu, Matei
    HEPATOLOGY, 2006, 44 (04) : 550A - 550A
  • [40] Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
    Yao-ren Hu
    Hua-dong Yan
    Guo-sheng Gao
    Cheng-liang Zhu
    Ji-fang Cheng
    Infection International(Electronic Edition), 2014, 3 (01) : 10 - 15
12345